Abstract
Breast cancer is the second most common cancer in women, making research over the different types of breast cancer a major concern. We decided to target two oncogenes located on the same chromosome, MDM2 and CDK4/6. We targeted MDM2 with AMG232, and CDK4/6 with ribociclib and measured different outcomes. We used cell lines ZR75-1 and MCF7 cell lines, as they show an overexpression of these targeted proteins. With this data, we were able to conclude that ribociclib and AMG232 work to decrease cell proliferation in ZR75-1 and MCF7 HR+ breast cancer cell lines.
Included in
Targeting MDM2 and CDK4/6 in HR+ Breast Cancer
Breast cancer is the second most common cancer in women, making research over the different types of breast cancer a major concern. We decided to target two oncogenes located on the same chromosome, MDM2 and CDK4/6. We targeted MDM2 with AMG232, and CDK4/6 with ribociclib and measured different outcomes. We used cell lines ZR75-1 and MCF7 cell lines, as they show an overexpression of these targeted proteins. With this data, we were able to conclude that ribociclib and AMG232 work to decrease cell proliferation in ZR75-1 and MCF7 HR+ breast cancer cell lines.